Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)

NCT00420680 ↗

Phase 3 Completed 120 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of 2.0 mg/kg and 4.0 mg/kg sugammadex given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium in cardiac patients

Timeline

Start: 2005-11-07
Primary completion: 2006-08-01
Completion: 2006-08-01

Publications

Results Dahl V, Pendeville PE, Hollmann MW, Heier T, Abels EA, Blobner M. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 2009 Oct;26(10):874-84. doi: 10.1097/EJA.0b013e32832c605b.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sugammadex	Other / unclassified	2 mg/kg	—
Subject	Sugammadex	Other / unclassified	4 mg/kg	—

Indications

No indication recorded.